Disc Medicine, Inc. (IRON)

NASDAQ

$92.01

+$0.16 (0.17%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$90.01$92.18

Open $92.16

52 Week Range

$30.82$99.50

Previous Close $91.85

Market Cap3.47B

Volume556.01K

Avg Volume512.73K

P/E (TTM)-17.87

EPS (TTM)$-5.15

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Disc Medicine, Inc.

DEC62025

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Source: GlobeNewsWire•9 days ago

WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hem...

OCT312025

Disc Medicine to Participate in Upcoming Investor Conferences

Source: GlobeNewsWire•45 days ago

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hem...

OCT21

Latest Press Releases for Disc Medicine, Inc.

DEC62025

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Source: GlobeNewsWire•9 days ago

OCT312025

Disc Medicine to Participate in Upcoming Investor Conferences

Source: GlobeNewsWire•45 days ago

OCT21

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Source: GlobeNewsWire•56 days ago

WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from ser...

OCT202025

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Source: GlobeNewsWire•56 days ago

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from ser...

OCT202025

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Source: GlobeNewsWire•57 days ago

WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hem...

OCT172025

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Source: GlobeNewsWire•59 days ago

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hem...

SEP302025

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Source: GlobeNewsWire•76 days ago

WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious he...